2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 211

The Epidemiology of Gout: Marked Increase in Incidence and Comorbidities over 20 Years

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 522

The Expression of mRNA for Peptidylarginine Deiminase Type 2 and Type 4 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 280

The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 543

The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 690

The Impact of Ankylosing Spondylitis in Turkey on Productivity at Work Outside Home and within the Household

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 427

The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 34

The Impact of Cardiovascular and Lung Disorder Morbidities on Physical Activity in People with Inflammatory Arthritis Compared to the General Population in the UK

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 592

The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Paneuropean Analysis of RA Registries

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy

9:00AM-11:00AM: Abstract Number: 36

The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 4

The Influence of Adipokines on the Interaction of Rheumatoid Arthritis Synovial Fibroblasts with Endothelial Cells

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1

The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of B Cells at the Inflammatory Foci

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 533

The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 762

The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 254

The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever: Long-Term Beneficial Effect in a Cohort of 13 Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 768

The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].